Hasit Joshipura, managing director, GSK India, said, "One of our growth plans is to partner with global pharmaceutical companies for licensing in important molecules. The agreement with Astellas is in line with our strategy."
The company hopes that micafungin will strengthen its presence in intensive care and will provide an excellent fit with oncology where GSK has a promising R&D pipeline.
On the Bombay Stock Exchange, the GSK's stocks were trading at Rs 1,055, up 1.04 per cent at 1054 IST.
